**Supplementary Table S1.** Basic demographic and clinical data of 30 healthcare workers who received BNT162b2 mRNA COVID-19 vaccine and were followed up to 8 months.

	Subject ID	Gender	COVID-19 severity
COVID-19 recovered individuals	R1	male	mild
	R2	female	mild
	R3	female	severe
<u>Š</u>	R4	female	mild
pu	R5	male	moderate
:= B	R6	male	mild
re	R7	female	mild
ve	R8	male	moderate
8	R9	female	mild
re	R10	female	mild
19	R11	male	mild
٥	R12	male	critical
>	R13	male	critical
8	R14	female	mild
	R15	female	mild
Mean±SD	1	-	-
	N1	male	na
	N2	female	na
	N3	male	na
	N4	female	na
als	N5	female	na
ηp	N6	female	na
<u>Š</u>	N7	male	na
pu	N8	female	na
e:	N9	male	na
Naïve individuals	N10	male	na
Sa	N11	male	na
_	N12	female	na
	N13	female	na
	N14	female	na
	N15	male	na
Mean±SD	-	-	-

na denotes not applicable

**Supplementary Table S2.** Basic demographic and clinical data of 125 healthcare workers who received BNT162b2 mRNA COVID-19 vaccine and were followed up to 6 months.

	COVID-19 recovered individuals	Naïve individuals
No. subjects	39	86
Age (years)		
Mean±SD	50.4±11.3	45.5±14.3
Gender		
- Male, n (%)	12 (31.6)	39 (45.3)
- Female, n (%)	26 (68.4)	47 (54.6)
COVID-19 severity		Na
- Asymptomatic/mild, n (%)	31 (79.5)	
- Moderate, n (%)	2 (5.1)	
- Severe, n (%)	2 (5.1)	
- Critical, n (%)	4 (10.3)	
Time from COVID-19 diagnosis°		na
to first vaccine dose (days)		
- Mean±SD	230.4±93.6	

na denotes not applicable

**Supplementary Table S3.** Basic demographic and clinical data of 14 healthcare workers who received booster BNT162b2 mRNA COVID-19 vaccine injection and were followed up to one week.

	Subject ID	Gender	COVID-19 severity
<u> </u>	RB1	female	severe
COVID-19 recovered individuals receiving booster dose	RB2	female	mild
COVID-19 recovered individuals ceiving boos	RB3	male	critical
VID-Cover cover ividu ing bo	RB4	male	moderate
CO C	RB5	female	mild
ece =: -	RB6	male	critical
	RB7	female	mild
Mean±SD	ı	-	-
S =	NB1	female	na
lividuals booster se	NB2	female	na
vid 200	NB3	male	na
indiv ing bo dose	NB4	female	na
i viri	NB5	male	na
Naïve individuals receiving booster dose	NB6	male	na
۷ ی	NB7	male	na
Mean±SD	-	-	-

na denotes not applicable

**Supplementary Table S4.** Basic demographic and clinical data of 14 individuals who were hospitalized for COVID-19 between March and April 2020 and followed up to 12 months from discharge.

	Subject ID	Gender	COVID-19 severity
	U1	male	moderate
recovered	U2	male	moderate
Ne Ne	U3	male	severe
000	U4	female	severe
	U5	male	moderate
Unvaccinated COVID-19 individuals	U6	male	severe
N D	U7	male	critical
d COVID-1	U8	male	critical
i g	U9	female	severe
ate	U10	female	critical
Ċ.	U11	female	moderate
/ac	U12	female	moderate
٦	U13	female	moderate
	U14	male	critical
Mean±SD	-	-	-

## Supplementary Table S5. List of all fluorochrome mAbs used for flow cytometric analysis of antigen specific T cells.

Antigen	Flurochrome	Clone	Company
TNF-α	FITC	6401.1111	BDBioscience
CD154	PE	TRAP1	BDBioscience
CD3	PerCP	SK7	BDBioscience
CD4	PE-Cy7	SK3	Invitrogen
CD8	Super Bright 600	SK1	eBioscience™
IL-2	APC	MQ1-17H12	BDBioscience
IFN-γ	Pacific Blue	B27	BioLegend
L/D	Fixable Viability Stain 780		BDBioscience

## Supplementary Table S6. List of all fluorochrome mAbs used for flow cytometric analysis of antigen specific B cells.

Antigen	Flurochrome	Clone	Company
CD19	APC-Vio770	LT19	Miltenyi
CD27	VioBright FITC	M-T271	Miltenyi
IgA	VioGreen	IS11-8E10	Miltenyi
IgG	VioBlue	IS11-3B2.2.3	Miltenyi
CD14	PerCP	TÜK4	Miltenyi
IgM	APC	PJ2-22H3	Miltenyi
CD3	PerCP	BW264/56	Miltenyi
7AAD			Miltenyi
Spike	PE		Miltenyi
Spike	PE-Vio770		Miltenyi